E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cystic Fibrosis with Pseudomoas aeuriginosa infection |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10011763 |
E.1.2 | Term | Cystic fibrosis lung |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to determine the bioavailability in the Tobramycin 100 PARI / eFlow treatment group compared to the TOBI® / PARI LC PLUS / PRONEB® ULTRA compressor treatment group. Both groups of patients will be treated during a period of 28 days, receiving the study medication twice a day.
1. Evaluation of serum and sputum levels of the new formulation Tobramycin 100 PARI containing 150 mg / 1.5 ml Tobramycin nebulized via eFlow®, compared with the registered TOBI® nebulized via PARI LC PLUS. Primary endpoint is plasma tobramycin levels at day 7. 2. Evaluation of safety data: safety of Tobramycin 100 PARI will be determined for 28 days treatment in 30 CF patients. The active control arm has 30 CF patients receiving TOBI standard therapy.
Primary endpoint: Pharmacokinetics: serum Tobramycin levels at day 7
|
|
E.2.2 | Secondary objectives of the trial |
- Sputum Tobramycin levels at days 1, 7 and 28, measured 10 minutes after end of inhalation. - Trough tobramycin plasma levels at days 1 and 28, measured before inhalation of study medication.
Tolerability:
- Bronchospasm: number and relative percentage of patients with bronchospasm (defined as a fall in FEV1 > 15% at 30 min after the end of inhalation) - Fall of FEV1 in percent from pre- to post treatment
Safety endpoints:
- Extreme cough or wheezing or onset of respiratory distress. - Frequency and severity of dyspnea. - Audiology: audiological alterations and signs of tinnitus will be recorded. - Proportion of subjects reporting advers events. - Proportion of subjects with laboratory test abnormalities.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients older than 8 years of age. - Subjects with documented CF: Documented sweat chloride > 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) or homozygosity for AF508 genetic mutation (or heterozygosity for two well characterized mutations) and two clinical findings consistent with CF. - Ability to perform reproducible spirometry. - Stable condition with no exacerbation requiring IV antibiotics or hospitalization within one months period prior to screening visit. - No change in FEV1 bigger than 20% from baseline within one month period prior to screening visit. - Documented P. aeruginosa presence in a sputum/throat culture within 6 months prior to screening or at least two consecutive positive P. aeruginosa cultures within one year. - FEV1 at least of 40% of predicted, based on gender, age and height. - Room air oximetry from at least 88% saturation.
|
|
E.4 | Principal exclusion criteria |
1. Use of an investigational drug within 30 days prior to study entry or during the trial. 2. Active drug and alcohol abuse. 3. Inability to handle the study inhalers or to inhale the test formulations. 4. Inability to adhere to the requirements of the protocol. 5. FEV1 lesst han 40% predicted. 6. Administration of any anti pseudomonas antibiotics by any route within 7 days prior to initial study drug administration, with the exception of macrolide, provided that these are taken as a maintenace therapy at least 6 weeks before entering the trial. 7. Severe respiratory infection within one month prior to screening, which requires hospital admission or treatment with intravenous antiobiotics 8. Positive urine pregnancy test. 9. Hemoptysis > 60 cc at any time within thirty days prior to study drug administration. 10. Known local or systemic hypersensitivity to aminoglycosides. 11. Serum creatinine = or greater than 1,2 mg/d, BUN = 20 mg/dl or greater, or an abnormal urine analysis defined as more than 1+ proteinuria in urinstix. 12.History of sputum culture or throat swab culture yielding B.cepacia in the previous 12 months and/or sputum or throat swab culture yielding B. cepacia at screening. 13. Presence of allergic bronchopulmonary aspergillosis (ABPA) as evidenced by positive cultures for aspergillosis, positive skin test and IgE>1000 IU. 14. Patients with right side heart failure. 15. Non-compliance with recommended pulmonary rehabilitation 16. Significant liver disease clinically diagnosed. 17. Patients with history of GI bleeding. 18. Patients with known or suspected neuromuscular dysfunction. 19. Patients with known or suspected auditory or vestibular dysfunction. 20. Women of childbearing potential and sexually active who are not already using a high effective method of contraception.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokinetics: serum Tobramycin levels at day 7: trough level, peak level and area under the curve (AUC).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Yes |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | Yes |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 4 |